WO1991000098A1 - Preparation anti-inflammatoire et son procede d'obtention - Google Patents
Preparation anti-inflammatoire et son procede d'obtention Download PDFInfo
- Publication number
- WO1991000098A1 WO1991000098A1 PCT/SU1989/000169 SU8900169W WO9100098A1 WO 1991000098 A1 WO1991000098 A1 WO 1991000098A1 SU 8900169 W SU8900169 W SU 8900169W WO 9100098 A1 WO9100098 A1 WO 9100098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- introduction
- dose
- days
- drug
- product
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 38
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 210000002826 placenta Anatomy 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 41
- 229940079593 drug Drugs 0.000 claims description 37
- 150000001261 hydroxy acids Chemical class 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 235000009421 Myristica fragrans Nutrition 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 239000001115 mace Substances 0.000 claims 1
- 230000008092 positive effect Effects 0.000 claims 1
- 239000012153 distilled water Substances 0.000 abstract description 9
- 239000002245 particle Substances 0.000 abstract description 6
- 238000005406 washing Methods 0.000 abstract description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 210000003954 umbilical cord Anatomy 0.000 abstract 2
- 150000000996 L-ascorbic acids Chemical class 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000725 suspension Substances 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 210000002307 prostate Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000282887 Suidae Species 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000012433 rusks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000004613 tight binding model Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
Definitions
- Tissue preparations made from the placenta are also known, which are used in veterinary gynecology. There are various ways of using these drugs, which in many respects depends on the activity of the drug. Well, for example, - 2 -
- the main task of the invention is to create a new one
- Task 30 ⁇ eshena ⁇ em, ch ⁇ claimed ⁇ e ⁇ a ⁇ a ⁇ , s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniyu, ⁇ eds ⁇ avlyae ⁇ s ⁇ b ⁇ y emulsion ⁇ u ⁇ viny ⁇ latsen ⁇ y chel ⁇ ve ⁇ s, dena ⁇ u ⁇ i ⁇ vann ⁇ y ⁇ l ⁇ m in dis ⁇ illi ⁇ vann ⁇ y v ⁇ de, imeschuyu ⁇ 2,5-3,0, ⁇ azme ⁇ chas ⁇ its not ⁇ evyshayuschy 0.4 mm s ⁇ de ⁇ zhaschuyu su ⁇ y ⁇ s ⁇ a ⁇ 1 , 65-3.0 to.%, Containing
- the claimed drug has a pronounced beneficial effect, and also is punitive.
- the drug is not - 3 - Toxic, also possesses a stimulating effect.
- the claimed preparation is used for the treatment and treatment of delay of ill-health, after-effects of illness and infertility in patients.
- the efficacy of the claimed 5 products for pharmaceutical purposes is 92-97, for medical purposes it is $ 84-92.
- the invention is also a method of receiving the claimed product.
- the inventive product delivers a white emulsion of its own, with a particle size of not more than 0.4 mm, having ⁇ 2.5-3.0, with a dry outlet of 1.65-3.0 wt. $, Which contains at least less than 0.04 mg of nucleic acids, protein of not less than 7.5 mg, hydroxy acids of not less than 0.85 mg.
- the influence of the claimed preparation on aseptic inflammation has been studied in 27 circulatory masses of body weight - 4 - 250-280 g, they divided the principle of analogs into 3 equal pears.
- the experimental inflammation was obtained by the method of experimental granuloma (preservation of the trauma of the cannula). Lively ⁇ -th group served as a control, the second group introduced 0.25 ml
- the 3rd group introduced a suspension of the placenta in a dose of 0.5 ml (31.25 mg).
- the drugs entered the back on the same day with the nursing regiment and on the 4th day. After 3 days, the animals were killed and weighted with wet and dried granulomas (values of exudation and
- both the preparation (claimed and the suspension of the placenta) cause an equal effect - a decrease in production by $ 25-26.
- the claimed preparation was administered at a dose of almost 10 times less than the suspension of the placenta.
- the preparations cause a similar effect - the reduction of the exudation by 15 CS and the introduction of a doze of the claimed preparation by 10 times less than the suspension.
- the claimed preparation is more active than suspension of the placenta in the same way as in the case of the treatment, cancer and exudation.
- 35 units of the principle of analogue for 5 groups: the second - the second, the second and third group is equal to the application of the same amount and for 3 days before the application of the declared amount of 0.5 ml (7 mg) 1.25 ml (17.5 mg), 4th and 5th group - 5 - Case injection of a suspension of the placenta in doses of 0.2 ml (12.5 mg) and 0.5 ml (31.25 mg) for live. Dosages are chosen according to the agreed-upon scale, which are suitable for providing comparable effects for the products. 5 Body sizes from a height of 40 cm, weight 500 g per side of the left foot. Rice is delivered by a non-intrusive diet (30 mg / kg). The length of the foot can be replaced with a dry water (each measurement is 5 times and the last one) before striking, after an hour and after I, 5, 7, 10 and 14 days after application
- the regressive unit is more suitable for the close dependence of the dose-effect and the effective dose for the treatment is calculated.
- the dose-effect and the effective dose are calculated.
- the activity of the claimed device is up to 5 times an automatic flow after 5 days 5.5 times higher than the activity of suspension of the placenta.
- the aseptic inflammation of the prostate gland is caused by stitching it with silk thread before tensile stress, the silk thread is not pulled, but
- the inventive preparation is administered once a week when I go back in a dose of 14 mg per animal. I keep daily every day (on one day a week), and then I need to keep my back in a dose of 0.5 ml (8 mg) for live exposure.
- the study of simple toxicity was performed on 18 mice of a weight of 18-20 g.
- the claimed preparation was administered with a dose of 0.2 ml (2.8 mg), 14 mg (14 mg), excluding 14 mg , respectively, 700 mg / kg.
- the last 5th dose is the maximum allowable for introducing to mice a handy and 700 times higher dose, which is used for cattle and pigs.
- the claimed drug was administered at a dose of 15 15 ml (2-0.G live), which is 420-7.
- mice, rats, and simple mice are good practice, as a result of this, we recommend that you use - 9 - a short introduction to this species of animals, in mice, pigs and little pigs, does not cause any toxic phenomena - they do not change the general housing, the livestock does not change. 5 Conducted a study of toxicity.
- the claimed product is administered in two groups in the following doses: the second group is 1.25 ml (17.5 mg), which is 85 times greater.
- Hemoglobin, erythrocytes, leukocytes are located at
- the claimed device does not take into account the functional state of the endocrine glands. - 12 -
- the irritating and allergizing effect of the claimed drug has been studied.
- the studies cited show that the claimed product does not have an irritating effect on tissue and does not have an allergenic effect.
- ⁇ ⁇ aches ⁇ ve ⁇ n ⁇ lya with lechebn ⁇ y purpose ⁇ imenyazh 7.5 ethyl ⁇ as ⁇ v ⁇ i ⁇ i ⁇ la $ 40 $ ⁇ as ⁇ v ⁇ e glyu ⁇ zy vv ⁇ dizh in a ⁇ u 1 ethyl ⁇ as ⁇ v ⁇ n ⁇ v ⁇ aina and ⁇ si ⁇ tsina in ⁇ l ⁇ s ⁇ ma ⁇ i vv ⁇ dizh y ⁇ d ⁇ s ⁇ l and d ⁇ ugie ⁇ e ⁇ a ⁇ a ⁇ y, ⁇ dna ⁇ not always desired ⁇ luchazh ⁇ ezul ⁇ a ⁇ .
- the inventive appliance is supplied in a dose of 20-30 ml.
- Declared ⁇ proceedingsparát was named ⁇ and the detention of the next. After entering the dose 30 ml after 9-12 hours after the body. After 24-36 hours, after the introduction of the claimed device, the suspect after the self-reliably separated. Treatment with 3 injections. The effective efficacy of the claimed pharmaceutical product when securing the trace of the trace was $ 70-85.
- the inventive preparation was used for the treatment of diseases of the present masses. Take care of the product and remove the udder. The inventive preparation was administered twice at a dose of 30 ml with an interval of 2-3 days.
- the inventive appliance was used for practical purposes in the first hours after the hotel. All rights reserved, after 4-5 hours after staying at the hotel, it’s delayed
- target product that provides a white emulsion with a particle size not exceeding 0.4 mm, with a dry content of 1.65-3.0 wt. $, Containing in I ml - 16 - nucleic acids of at least 0.04 mg, protein of at least 7.5 mg of hydroxy acids of at least 0.85 mg.
- the yield of the target product is 98.
- the claimed preparation was used in two cases for 162 patients who became ill with endometriosis with a chronic course of the disease.
- the preparation is lively in a dose of 20 ml
- the inventive was used in 43 cases at the time of detention of the trace.
- the drug was administered live after 9-12 hours after the body after each 30 ml. At 41 days after 24-36 hours after the introduction of the drug, the arrogant after it was self-reliably separated.
- the inventive was used for the removal of the udder. Observation is 19 days on board.
- the claimed medication is beneficial in the treatment of medication and the treatment of medication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Une préparation anti-inflammatoire se compose d'une émulsion de cordon ombilical de placenta humain, dénaturé par du chlore, dans de l'eau distillée ayant un pH compris entre 2,5 et 3,0, la taille des particules ne dépassant pas 0,4 mm, comprenant un résidu sec compris entre 1,65 et 3,0 % en poids, et contenant dans un 1 ml non moins de 0,04 mg d'acides nucléiques, non moins de 7,5 mg de protéine et non moins de 0,85 mg d'acides ascorbiques. Un procédé d'obtention de ladite préparation consiste à laver le cordon ombilical de placenta, à le désintégrer et à le soumettre à une dénaturation par traitement à l'aide d'une solution de chlore dans de l'eau distillée, de sorte que sa concentration ne dépasse 0,21 % en poids, après quoi la masse obtenue est extraite de la solution et est traitée à l'aide d'eau distillée jusqu'à obtention d'un pH de 3,0, puis on élimine l'eau, on mélange à nouveau la masse tissulaire à l'eau distillée, et on disperse le mélange jusqu'à obtention d'une grosseur de particule ne dépassant pas 0,4 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1989/000169 WO1991000098A1 (fr) | 1989-06-23 | 1989-06-23 | Preparation anti-inflammatoire et son procede d'obtention |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1989/000169 WO1991000098A1 (fr) | 1989-06-23 | 1989-06-23 | Preparation anti-inflammatoire et son procede d'obtention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991000098A1 true WO1991000098A1 (fr) | 1991-01-10 |
Family
ID=21617492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SU1989/000169 WO1991000098A1 (fr) | 1989-06-23 | 1989-06-23 | Preparation anti-inflammatoire et son procede d'obtention |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1991000098A1 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2167664C2 (ru) * | 1998-12-28 | 2001-05-27 | Научный центр клинической и экспериментальной медицины СО РАМН | Средство противовоспалительного иммуномодулирующего действия |
| JP2007106760A (ja) * | 2005-09-16 | 2007-04-26 | Kenji Yoshida | 造血幹細胞増殖剤 |
| RU2355405C2 (ru) * | 2007-05-17 | 2009-05-20 | Михаил Аркадьевич Шурдов | Пептидный экстракт плаценты и способ его изготовления |
| EP1941890A4 (fr) * | 2005-09-16 | 2009-08-05 | Kenji Yoshida | Proliferateur de cellules souches hematopoietiques |
| RU2665379C2 (ru) * | 2016-12-07 | 2018-08-29 | Общество С Ограниченной Ответственностью "Гамаветфарм" | Средство для стимуляции выработки соматотропного гормона гипофизом и способ его получения |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1380056A (en) * | 1970-12-22 | 1975-01-08 | Behringwerke Ag | Process for isolating a fibrin-stabilizing factor |
| GB1380270A (en) * | 1970-12-22 | 1975-01-08 | Behringwerke Ag | Process for isolating a fibrin-stabilizing factor |
| US4054648A (en) * | 1973-08-30 | 1977-10-18 | Morinaga Milk Industry Co., Ltd. | Process for preparing a therapeutic agent |
| US4302385A (en) * | 1978-12-19 | 1981-11-24 | Behringwerke Aktiengesellschaft | Placenta-specific tissue protein PP10 |
| GB2110531A (en) * | 1981-11-05 | 1983-06-22 | East Grinstead Research Trust | Wound healing composition prepared from amnion |
| EP0302459A2 (fr) * | 1987-08-04 | 1989-02-08 | Sumitomo Pharmaceuticals Company, Limited | Facteur de croissance cellulaire stable à la température dérivé du placenta humain et méthode pour sa production |
-
1989
- 1989-06-23 WO PCT/SU1989/000169 patent/WO1991000098A1/fr unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1380056A (en) * | 1970-12-22 | 1975-01-08 | Behringwerke Ag | Process for isolating a fibrin-stabilizing factor |
| GB1380270A (en) * | 1970-12-22 | 1975-01-08 | Behringwerke Ag | Process for isolating a fibrin-stabilizing factor |
| US4054648A (en) * | 1973-08-30 | 1977-10-18 | Morinaga Milk Industry Co., Ltd. | Process for preparing a therapeutic agent |
| US4302385A (en) * | 1978-12-19 | 1981-11-24 | Behringwerke Aktiengesellschaft | Placenta-specific tissue protein PP10 |
| GB2110531A (en) * | 1981-11-05 | 1983-06-22 | East Grinstead Research Trust | Wound healing composition prepared from amnion |
| EP0302459A2 (fr) * | 1987-08-04 | 1989-02-08 | Sumitomo Pharmaceuticals Company, Limited | Facteur de croissance cellulaire stable à la température dérivé du placenta humain et méthode pour sa production |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2167664C2 (ru) * | 1998-12-28 | 2001-05-27 | Научный центр клинической и экспериментальной медицины СО РАМН | Средство противовоспалительного иммуномодулирующего действия |
| JP2007106760A (ja) * | 2005-09-16 | 2007-04-26 | Kenji Yoshida | 造血幹細胞増殖剤 |
| EP1941890A4 (fr) * | 2005-09-16 | 2009-08-05 | Kenji Yoshida | Proliferateur de cellules souches hematopoietiques |
| RU2355405C2 (ru) * | 2007-05-17 | 2009-05-20 | Михаил Аркадьевич Шурдов | Пептидный экстракт плаценты и способ его изготовления |
| RU2665379C2 (ru) * | 2016-12-07 | 2018-08-29 | Общество С Ограниченной Ответственностью "Гамаветфарм" | Средство для стимуляции выработки соматотропного гормона гипофизом и способ его получения |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Osborne et al. | The incidence of phosphatic urinary calculi in rats fed on experimental rations | |
| WO1994001099A1 (fr) | Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectrice et anti-cholera | |
| EP0431164A4 (en) | Preparation with an anti-inflammatory, lactogenous and stimulating action, and method of obtaining it | |
| Bartholow | A practical treatise on materia medica and therapeutics | |
| WO1995022336A1 (fr) | Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires | |
| WO1995011659A2 (fr) | Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation | |
| CN106577480A (zh) | 一种提高黄牛抗病力的养殖方法 | |
| WO1991000098A1 (fr) | Preparation anti-inflammatoire et son procede d'obtention | |
| Kellogg | Autointoxication; Or, Intestinal Toxemia | |
| WO1997048405A1 (fr) | Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes | |
| RU2114625C1 (ru) | Способ получения биостимулирующих средств | |
| Clare | The endocrine system and | |
| RU2136303C1 (ru) | Способ получения средства для лечения ларвального и стробилярного эхинококкозов "чеблин ск-1" | |
| Jacobi | Therapeutics of infancy and childhood | |
| WO1992006696A1 (fr) | Procede d'obtention d'une preparation bioactive a partir du sang | |
| Sah | A REVIEW ARTICLE ON GARVISHA: CONCEPTUAL STUDY | |
| Hogg | The domestic medical and surgical guide for the nursery, the cottage, and the bush | |
| RU2397772C1 (ru) | Лекарственное средство для лечения и профилактики доброкачественной гиперплазии предстательной железы и эректильной дисфункции у мужчин | |
| CN109331022A (zh) | 提高女性卵巢功能改善女性皮肤的组合物和制备工艺 | |
| Wells | Sound teeth in a Sound Body | |
| ITCH | MAC.~ MC. MACRACANTHORHYNCHUS HIRU | |
| Jacobi | The intestinal diseases of infancy and childhood: Physiology, hygiene, pathology and therapeutics | |
| Brunton | On Disorders of Assimilation, Digestion Etc... | |
| Clarke | The People's Horse, Cattle, Sheep, & Swine Doctor... | |
| WO2003090556A1 (fr) | Composition biologiquement active |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |